Details for New Drug Application (NDA): 202107
✉ Email this page to a colleague
NDA 202107 describes KORLYM, which is a drug marketed by Corcept Therap and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the KORLYM profile page.
The generic ingredient in KORLYM is mifepristone. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mifepristone profile page.
The generic ingredient in KORLYM is mifepristone. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mifepristone profile page.
Summary for 202107
| Tradename: | KORLYM |
| Applicant: | Corcept Therap |
| Ingredient: | mifepristone |
| Patents: | 18 |
Pharmacology for NDA: 202107
| Mechanism of Action | Progestational Hormone Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for 202107
Suppliers and Packaging for NDA: 202107
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| KORLYM | mifepristone | TABLET;ORAL | 202107 | NDA | Corcept Therapeutics Incorporated | 76346-073 | 76346-073-01 | 28 TABLET in 1 BOTTLE (76346-073-01) |
| KORLYM | mifepristone | TABLET;ORAL | 202107 | NDA | Corcept Therapeutics Incorporated | 76346-073 | 76346-073-02 | 280 TABLET in 1 BOTTLE (76346-073-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
| Approval Date: | Feb 17, 2012 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Aug 12, 2036 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATING CUSHING'S SYNDROME | ||||||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Jan 18, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATING CUSHING'S SYNDROME | ||||||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Apr 20, 2036 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATING CUSHING'S SYNDROME | ||||||||
Complete Access Available with Subscription
